Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2025 21:26 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
September 18, 2025 16:05 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
August 14, 2025 16:25 ET | Source: Reviva Pharmaceuticals

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– –...
June 26, 2025 08:40 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
June 25, 2025 16:17 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
June 05, 2025 08:00 ET | Source: Reviva Pharmaceuticals

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
June 02, 2025 07:00 ET | Source: Reviva Pharmaceuticals

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation...
May 20, 2025 08:00 ET | Source: Reviva Pharmaceuticals

Reviva to Participate in Upcoming Investor Conferences in May 2025

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
May 15, 2025 16:05 ET | Source: Reviva Pharmaceuticals

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE...
May 13, 2025 08:00 ET | Source: Reviva Pharmaceuticals

Reviva to Participate in the A.G.P. Healthcare Company Showcase

CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...